HONG KONG, Feb. 12, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460) ("Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group and Hetero Labs Limited ("Hetero"), a company registered under the laws of India, reached a framework cooperation agreement (the "Cooperation") in the pharmaceutical manufacturing area after several rounds of discussion.
Under the terms of the framework cooperation agreement, the Cooperation includes research and development ("R&D"), product registration, technology transfer, raw materials supply and local manufacturing and commercialization of drugs in the fields of cardiovascular, cerebrovascular, neurology and anti-infectives including novel coronavirus (2019-nCoV), etc.
Backed by over 25 years of expertise in the pharmaceutical industry, Hetero is the world's leading producer of anti-retroviral drugs for the treatment of HIV/AIDS. Hetero caters about 40% of the identified HIV/AIDS patients globally through around 30 anti-retroviral products combinations. In addition, Hetero is growing as a reliable partner in the industry specializing in major therapeutic categories such as oncology, cardiovascular, neurology, hepatitis, nephrology, urology, diabetes, ophthalmology and immunology, etc., with around 300 products in the portfolio.
The signing of this framework cooperation agreement will achieve a win-win situation in which the two parties complement each other's strengths and jointly accelerate their development. On one hand, Hetero's anti-viral and anti-infection products will be introduced to China by Sihuan Phamaceutical which is equipped with standardized production capacity and strong marketing capabilities for local production and sales. This will also enrich the Group's R&D and product pipeline. On the other hand, Hetero will explore the great potential in the China market.
Dr. Che Fengsheng, Chairman and Executive Director of Sihuan Pharmaceutical said, "Based on the prevalence of the novel coronavirus infection pneumonia in China, both parties agreed to take the introduction, development and production of new coronavirus drugs as a priority issue, giving priority and contributing to China's fight against the pandemic ! "
- End -
About Hetero Labs Limited
Headquartered in Hyderabad, India, Hetero is one of India's leading generic pharmaceutical companies and one of the world's largest producers of anti-retroviral drugs for the treatment of HIV/AIDS. Backed by over 25 years of expertise in the pharmaceutical industry, Herero's strategic business areas spread across APIs, generics, biosimilars, custom pharmaceutical services and branded generics. Hetero is globally recognized for its strengths in research and development, manufacturing and commercialization of a wide range of products. Hetero caters about 40% of the identified HIV/AIDS patients globally through 30+ ARV products combinations . Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, audited and approved by stringent regulatory authorities like U.S. FDA, EU, TGA-Australia, MCC-South Africa and others. Hetero is growing as leader and reliable partner of choice in the major therapeutic categories such as HIV/AIDS, oncology, cardiovascular, neurology, hepatitis, nephrology, urology, diabetes, ophthalmology, hepatology and immunology etc., with over 300 products in the portfolio.
About Sihuan Pharmaceutical Holdings Group Ltd.
Founded in 2001, Sihuan Pharmaceutical is a pharmaceutical group with 21 subsidiaries and integrated R&D, production and marketing and sales capabilities. Because of the continuing efforts over the past decade, Sihuan Pharmaceutical has formed a R&D platform with over 1,000 researchers conducting more than 110 pharmaceutical research projects currently. More than 300 patents on innovative drugs were granted in China and over 80 are PCT patents, covering pipeline projects including important areas of diabetes, oncology, anti-infectives and non-alcoholic steatohepatitis etc.
